Patents by Inventor Leewen Lin

Leewen Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME
    Publication number: 20180238895
    Abstract: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Application
    Filed: January 12, 2018
    Publication date: August 23, 2018
    Inventors: Rong-Hwa LIN, Leewen LIN, Shih-Yao LIN, Shu-Hua LEE
  • ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME
    Publication number: 20160139131
    Abstract: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Application
    Filed: October 20, 2015
    Publication date: May 19, 2016
    Inventors: Rong-Hwa LIN, Leewen LIN, Shih-Yao LIN, Shu-Hua LEE
  • Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
    Patent number: 9334329
    Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: May 10, 2016
    Assignee: BioAlliance C.V.
    Inventors: Shih-Yao Lin, Leewen Lin, Yu-Ying Tsai
  • Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
    Patent number: 9193794
    Abstract: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: November 24, 2015
    Assignee: BioAlliance C.V.
    Inventors: Rong-Hwa Lin, Leewen Lin, Shih-Yao Lin, Shu-Hua Lee
  • ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME
    Publication number: 20140105899
    Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Application
    Filed: September 24, 2013
    Publication date: April 17, 2014
    Applicant: BioAlliance C.V.
    Inventors: Shih-Yao LIN, Leewen LIN, Yu-Ying TSAI
  • Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
    Patent number: 8568718
    Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: October 29, 2013
    Assignee: Bioalliance C.V.
    Inventors: Shih-Yao Lin, Leewen Lin, Yu-Ying Tsai
  • ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME
    Publication number: 20110280888
    Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Application
    Filed: June 8, 2011
    Publication date: November 17, 2011
    Applicant: BioAlliance C.V.
    Inventors: Shih-Yao LIN, Leewen LIN, Yu-Ying TSAI
  • Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
    Patent number: 7982017
    Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: July 19, 2011
    Assignee: BioAlliance C.V.
    Inventors: Shih-Yao Lin, Leewen Lin, Yu-Ying Tsai
  • ANTI-EPCAM ANTIBODIES THAT INDUCE APOPTOSIS OF CANCER CELLS AND METHODS USING SAME
    Publication number: 20110165161
    Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to epithelial cell adhesion/activating molecule EpCAM expressed on cancer cells and induce cancer cell apoptosis. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Application
    Filed: December 23, 2010
    Publication date: July 7, 2011
    Inventors: Shih-Yao LIN, Leewen Lin, Feng-Lin Chiang, Shu-Hua Lee, Yu-Ying Tsai
  • ANTIBODIES RECOGNIZING OXYGEN-REGULATED PROTEIN 150 EXPRESSED ON CANCER CELLS AND METHODS OF USING SAME
    Publication number: 20100135991
    Abstract: The present invention provides novel antibodies that specifically bind to an ORP150 polypeptide expressed of the cell surface of plasmacytoma, multiple myeloma, colorectal cancer cells, gastric cancer cells, or esophageal cancer cells. These antibodies can be used in a variety of diagnostic and therapeutic methods.
    Type: Application
    Filed: November 17, 2009
    Publication date: June 3, 2010
    Inventors: Chiu-Chen Huang, Shih-Yao Lin, Leewen Lin
  • ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME
    Publication number: 20100124551
    Abstract: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Application
    Filed: January 20, 2010
    Publication date: May 20, 2010
    Inventors: Rong-Hwa LIN, Leewen Lin, Shih-Yao Lin, Shu-Hua Lee
  • Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
    Patent number: 7674605
    Abstract: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: March 9, 2010
    Assignee: BioAlliance C.V.
    Inventors: Rong-Hwa Lin, Leewen Lin, Shih-Yao Lin, Shu-Hua Lee
  • ANTIBODIES RECOGNIZING A CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS USING SAME
    Publication number: 20090191221
    Abstract: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Application
    Filed: December 18, 2008
    Publication date: July 30, 2009
    Inventors: Shih-Yao LIN, Leewen Lin, Yu-Ying Tsai
  • Prostaglandin reductase inhibitors
    Publication number: 20090124688
    Abstract: A method of inhibiting 15-keto prostaglandin-?13-reductase 2 by contacting 15-keto prostaglandin-?13-reductase 2 with an aryl compound of Formula (I), (II), (III), or (IV) shown herein. Also disclosed are methods of treating peroxisome proliferators-activated receptor related diseases and lowering blood glucose levels by administering to a subject in need thereof an effective amount of such an aryl compound.
    Type: Application
    Filed: January 8, 2007
    Publication date: May 14, 2009
    Inventors: Rong-Hwa Lin, Leewen Lin, Shih-Yao Lin, Shu-Hua Lee
  • Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
    Publication number: 20080171043
    Abstract: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
    Type: Application
    Filed: June 7, 2007
    Publication date: July 17, 2008
    Inventors: Rong-Hwa Lin, Leewen Lin, Shih-Yao Lin, Shu-Hua Lee